非定型抗酸菌症治療の世界市場レポート 2025年

非定型抗酸菌症治療の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.9％で30億2,000万米ドルに成長します。予測期間における成長の原動力は、人口の高齢化、マクロライド系抗生物質に対する需要の高まり、希少疾病の治療への注目の高まり、医療アクセスの拡大、非結核性抗酸菌症に対する臨床試験の増加であると予想されます。予測期間における主な動向としては、迅速分子診断法の発展、標的薬治療法の開発、感染管理における遠隔医療の統合、抗菌薬耐性研究への投資の増加、治療計画における人工知能の利用などが挙げられます。

感染症の有病率の増加は、今後数年間の非定型抗酸菌症治療市場の成長を促進すると予想されます。感染症は、細菌、ウイルス、真菌などの微生物が体内に侵入して増殖し、症状や病気を引き起こすことで発生します。感染症の増加は、主に抗菌剤耐性の増加によるもので、標準的な治療法の有効性を低下させ、病原体をより容易に拡散させます。非定型抗酸菌症治療は、非結核性抗酸菌病原体を標的として排除し、炎症を抑え、さらなる病気の進行を防ぐことで、これらの感染症に対処します。例えば、2023年11月、米国疾病予防管理センター（CDC）は、2022年に米国で8,331人の結核患者が発生し、2021年から5.9％増加したと報告しました。したがって、感染症の有病率の上昇は、非定型抗酸菌症治療市場の成長を促進する重要な要因です。

また、個別化治療に対する需要の高まりも市場成長に寄与するとみられています。個別化治療とは、個人固有の遺伝的、生物学的、環境的要因に合わせた治療を指し、治療効果を最適化します。このような治療法の需要は、主にゲノミクスとバイオテクノロジーの進歩により、個人の遺伝的プロファイルに合わせてカスタマイズされた治療法の開発が可能になり、有効性の向上と副作用の軽減が図られるようになったことが背景にあります。非定型抗酸菌症治療は、患者固有の遺伝的特徴や臨床的特徴に基づいてオーダーメイドの治療戦略を可能にするため、個別化治療において重要な役割を果たしています。例えば、2024年2月、個別化医療連合（Personalized Medicine Coalition）は、2023年にFDAが希少疾患に対する新たな個別化治療を16件承認したと報告しました。このように、個別化治療に対する需要の高まりが、非定型抗酸菌症治療市場の成長を後押ししています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の非定型抗酸菌症治療のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の非定型抗酸菌症治療市場：成長率分析
• 世界の非定型抗酸菌症治療市場の実績：規模と成長、2019～2024年
• 世界の非定型抗酸菌症治療市場の予測：規模と成長、2024～2029年、2034年
• 世界の非定型抗酸菌症治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の非定型抗酸菌症治療市場：治療タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 抗生物質療法
• 外科的介入
• 併用療法
• 支持療法
• 世界の非定型抗酸菌症治療市場：疾患別、実績と予測、2019～2024年、2024～2029年、2034年
• 非定型抗酸菌性肺感染症
• 播種性感染症
• 皮膚および軟部組織感染症
• 世界の非定型抗酸菌症治療市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口
• 静脈内
• 局所
• 世界の非定型抗酸菌症治療市場：患者タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 免疫不全患者
• 免疫不全のない患者
• 小児患者
• 世界の非定型抗酸菌症治療市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• クリニック
• 在宅ヘルスケア環境
• 世界の非定型抗酸菌症治療市場：抗生物質療法のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• マクロライド
• リファマイシン
• エタンブトール
• アミノグリコシド
• フルオロキノロン
• 世界の非定型抗酸菌症治療市場：外科的介入のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 肺切除
• リンパ節切除
• 皮膚および軟部組織のデブリードマン
• 膿瘍ドレナージ
• 気管支鏡介入
• 世界の非定型抗酸菌症治療市場：併用療法のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• マクロライド系薬剤3剤併用療法
• マクロライド＋注射用アミノグリコシド
• マクロライド＋フルオロキノロン＋エタンブトール
• 世界の非定型抗酸菌症治療市場：支持療法のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 栄養サポート
• 呼吸療法
• 疼痛管理
• 心理的サポート
• 免疫サポートサプリメント

第7章 地域別・国別分析

• 世界の非定型抗酸菌症治療市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の非定型抗酸菌症治療市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 非定型抗酸菌症治療市場：競合情勢
• 非定型抗酸菌症治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bayer AG
• Sanofi S.A.
• Bristol-Myers Squibb
• AstraZeneca PLC
• Novartis AG
• GlaxoSmithKline plc
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Zydus Pharmaceuticals
• Lupin Limited
• Gland Pharma Limited
• Saphnix Lifesciences Pvt. Ltd.
• Gentec Pharmaceutical Group
• Octavius Pharma Pvt. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 非定型抗酸菌症治療市場2029年：新たな機会を提供する国
• 非定型抗酸菌症治療市場2029年：新たな機会を提供するセグメント
• 非定型抗酸菌症治療市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Atypical mycobacteriosis treatment involves managing infections caused by nontuberculous mycobacteria (NTM), which are a group of mycobacterial species that do not lead to tuberculosis. These infections can affect areas such as the lungs, skin, and lymph nodes, and are often more resistant to standard tuberculosis therapies. Treatment generally requires a combination of antibiotics, including macrolides, rifamycins, and ethambutol, usually over an extended period.

The primary treatment options for atypical mycobacteriosis include antibiotic therapy, surgical interventions, combination therapy, and supportive care. Antibiotic therapy typically consists of long-term use of targeted antibiotics such as macrolides, aminoglycosides, and fluoroquinolones to eliminate or control the growth of atypical mycobacteria and prevent relapse. This approach is applied to various infections, including lung infections, disseminated infections, and skin or soft tissue infections, with administration via oral, intravenous, or topical routes. Treatment is provided to diverse patient groups, including immunocompromised individuals, non-immunocompromised patients, and children, and is delivered by different healthcare providers, such as hospitals, clinics, and home care settings.

The atypical mycobacteriosis treatment market research report is one of a series of new reports from The Business Research Company that provides atypical mycobacteriosis treatment market statistics, including atypical mycobacteriosis treatment industry global market size, regional shares, competitors with a atypical mycobacteriosis treatment market share, atypical mycobacteriosis treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the atypical mycobacteriosis treatment industry. This atypical mycobacteriosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The atypical mycobacteriosis treatment market size has grown strongly in recent years. It will grow from $2.26 billion in 2024 to $2.40 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. Growth during the historic period can be attributed to the rising prevalence of HIV, improved diagnostic techniques, increased awareness of mycobacterial infections, greater use of immunosuppressive therapies, and the expansion of infectious disease research.

The atypical mycobacteriosis treatment market size is expected to see strong growth in the next few years. It will grow to $3.02 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. Growth in the forecast period is expected to be driven by the aging population, rising demand for macrolide antibiotics, greater focus on treatments for orphan diseases, expanded healthcare access, and more clinical trials for nontuberculous mycobacterial infections. Key trends in the forecast period include advancements in rapid molecular diagnostics, the development of targeted drug therapies, the integration of telemedicine for infection management, increased investment in antimicrobial resistance research, and the use of artificial intelligence in treatment planning.

The increasing prevalence of infections is expected to drive the growth of the atypical mycobacteriosis treatment market in the coming years. Infections occur when microorganisms such as bacteria, viruses, or fungi invade and multiply in the body, leading to symptoms or disease. The rise in infections is primarily due to increasing antimicrobial resistance, which diminishes the effectiveness of standard treatments and allows pathogens to spread more easily. Atypical mycobacteriosis treatment addresses these infections by targeting and eliminating non-tuberculous mycobacterial pathogens, reducing inflammation, and preventing further disease progression. For example, in November 2023, the Centers for Disease Control and Prevention (CDC) reported that the United States recorded 8,331 tuberculosis cases in 2022, marking a 5.9% increase from 2021. Therefore, the rising prevalence of infections is a key factor driving the growth of the atypical mycobacteriosis treatment market.

The growing demand for personalized therapies is also expected to contribute to market growth. Personalized therapies refer to medical treatments that are tailored to an individual's unique genetic, biological, and environmental factors, optimizing treatment effectiveness. The demand for such therapies is mainly driven by advancements in genomics and biotechnology, which enable the development of treatments customized to an individual's genetic profile, improving efficacy and reducing side effects. Atypical mycobacteriosis treatment plays a crucial role in personalized therapies, as it allows for tailored treatment strategies based on a patient's specific genetic and clinical characteristics. For instance, in February 2024, the Personalized Medicine Coalition reported that in 2023, the FDA approved 16 new personalized treatments for rare diseases, a significant increase from just six approved in 2022. As such, the growing demand for personalized therapies is helping to fuel the growth of the atypical mycobacteriosis treatment market.

The rising incidence of chronic obstructive pulmonary disease (COPD) is also expected to drive the market forward. COPD refers to a group of progressive lung diseases, including emphysema and chronic bronchitis, that cause airflow obstruction and breathing problems. The increase in COPD cases is largely attributed to tobacco smoke, as prolonged exposure to harmful chemicals in tobacco damages the lungs and airways, leading to chronic inflammation and reduced airflow. Atypical mycobacteriosis treatment aids COPD management by reducing the bacterial load and inflammation caused by non-tuberculous mycobacteria, which can worsen respiratory symptoms and accelerate disease progression. For instance, in June 2024, the Australian Institute of Health and Welfare reported that COPD accounted for 3.6% of Australia's total disease burden in 2023, representing 50% of the total burden from respiratory conditions, up from 2.5% in 2022, reflecting a 44% increase in disease burden. Therefore, the rising incidence of COPD is driving the growth of the atypical mycobacteriosis treatment market.

Major players in the atypical mycobacteriosis treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Zydus Pharmaceuticals, Lupin Limited, Gland Pharma Limited, Saphnix Lifesciences Pvt. Ltd., Gentec Pharmaceutical Group, and Octavius Pharma Pvt. Ltd.

North America was the largest region in the atypical mycobacteriosis treatment market in 2024. The regions covered in atypical mycobacteriosis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the atypical mycobacteriosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The atypical mycobacteriosis treatment market consists of revenues earned by entities by providing services such as diagnosis and screening, consultation and care management, surgical intervention, patient education and support services, telemedicine services, inpatient and outpatient care, personalized treatment plans, pharmacovigilance and drug monitoring, nutritional support and counseling, and laboratory and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The atypical mycobacteriosis treatment market also includes sales of clarithromycin, azithromycin, rifampin, ethambutol, amikacin, streptomycin, rifabutin, pyrazinamide, interferons, probiotics, pulmonary inhalers, mucolytics, chronic infection management treatments, and diagnostic tools. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Atypical Mycobacteriosis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on atypical mycobacteriosis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for atypical mycobacteriosis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The atypical mycobacteriosis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Antibiotic Therapy; Surgical Interventions; Combination Therapy; Supportive Care
• 2) By Type Of Disease: Atypical Mycobacterial Lung Infections; Disseminated Infections; Skin And Soft Tissue Infections
• 3) By Route Of Admission: Oral; Intravenous; Topical
• 4) By Patient Type: Immuncompromised Patients; Non-Immunocompromised Patients; Pediatric Patients
• 5) By End Users: Hospitals; Clinics; Home Healthcare Settings
• Subsegments:
• 1) By Antibiotic Therapy: Macrolides; Rifamycins; Ethambutol; Aminoglycosides; Fluoroquinolones
• 2) By Surgical Interventions: Pulmonary Resection; Lymph Node Excision; Skin And Soft Tissue Debridement; Abscess Drainage; Bronchoscopic Interventions
• 3) By Combination Therapy: Macrolide-Based Triple Drug Regimen; Macrolide Plus Injectable Aminoglycoside; Macrolide Plus Fluoroquinolone And Ethambutol
• 4) By Supportive Care: Nutritional Support; Respiratory Therapy; Pain Management; Psychological Support; Immune Support Supplements
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Atypical Mycobacteriosis Treatment Market Characteristics

3. Atypical Mycobacteriosis Treatment Market Trends And Strategies

4. Atypical Mycobacteriosis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Atypical Mycobacteriosis Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Atypical Mycobacteriosis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Atypical Mycobacteriosis Treatment Market Growth Rate Analysis
• 5.4. Global Atypical Mycobacteriosis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Atypical Mycobacteriosis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Atypical Mycobacteriosis Treatment Total Addressable Market (TAM)

6. Atypical Mycobacteriosis Treatment Market Segmentation

• 6.1. Global Atypical Mycobacteriosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antibiotic Therapy
• Sugical Interventions
• Combination Therapy
• Supportive Care
• 6.2. Global Atypical Mycobacteriosis Treatment Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Atypical Mycobacterial Lung Infections
• Disseminated Infections
• Skin And Soft Tissue Infections
• 6.3. Global Atypical Mycobacteriosis Treatment Market, Segmentation By Route Of Admission, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• Topical
• 6.4. Global Atypical Mycobacteriosis Treatment Market, Segmentation By Patient Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immuncompromised Patients
• Non-Immunocompromised Patients
• Pediatric Patients
• 6.5. Global Atypical Mycobacteriosis Treatment Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Home Healthcare Settings
• 6.6. Global Atypical Mycobacteriosis Treatment Market, Sub-Segmentation Of Antibiotic Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Macrolides
• Rifamycins
• Ethambutol
• Aminoglycosides
• Fluoroquinolones
• 6.7. Global Atypical Mycobacteriosis Treatment Market, Sub-Segmentation Of Surgical Interventions, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pulmonary Resection
• Lymph Node Excision
• Skin And Soft Tissue Debridement
• Abscess Drainage
• Bronchoscopic Interventions
• 6.8. Global Atypical Mycobacteriosis Treatment Market, Sub-Segmentation Of Combination Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Macrolide-Based Triple Drug Regimen
• Macrolide Plus Injectable Aminoglycoside
• Macrolide Plus Fluoroquinolone And Ethambutol
• 6.9. Global Atypical Mycobacteriosis Treatment Market, Sub-Segmentation Of Supportive Care, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nutritional Support
• Respiratory Therapy
• Pain Management
• Psychological Support
• Immune Support Supplements

7. Atypical Mycobacteriosis Treatment Market Regional And Country Analysis

• 7.1. Global Atypical Mycobacteriosis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Atypical Mycobacteriosis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Atypical Mycobacteriosis Treatment Market

• 8.1. Asia-Pacific Atypical Mycobacteriosis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Atypical Mycobacteriosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Atypical Mycobacteriosis Treatment Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Atypical Mycobacteriosis Treatment Market, Segmentation By Route Of Admission, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Atypical Mycobacteriosis Treatment Market

• 9.1. China Atypical Mycobacteriosis Treatment Market Overview
• 9.2. China Atypical Mycobacteriosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Atypical Mycobacteriosis Treatment Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Atypical Mycobacteriosis Treatment Market, Segmentation By Route Of Admission, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Atypical Mycobacteriosis Treatment Market

• 10.1. India Atypical Mycobacteriosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Atypical Mycobacteriosis Treatment Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Atypical Mycobacteriosis Treatment Market, Segmentation By Route Of Admission, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Atypical Mycobacteriosis Treatment Market

• 11.1. Japan Atypical Mycobacteriosis Treatment Market Overview
• 11.2. Japan Atypical Mycobacteriosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Atypical Mycobacteriosis Treatment Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Atypical Mycobacteriosis Treatment Market, Segmentation By Route Of Admission, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Atypical Mycobacteriosis Treatment Market

• 12.1. Australia Atypical Mycobacteriosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Atypical Mycobacteriosis Treatment Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Atypical Mycobacteriosis Treatment Market, Segmentation By Route Of Admission, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Atypical Mycobacteriosis Treatment Market

• 13.1. Indonesia Atypical Mycobacteriosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Atypical Mycobacteriosis Treatment Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Atypical Mycobacteriosis Treatment Market, Segmentation By Route Of Admission, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Atypical Mycobacteriosis Treatment Market

• 14.1. South Korea Atypical Mycobacteriosis Treatment Market Overview
• 14.2. South Korea Atypical Mycobacteriosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Atypical Mycobacteriosis Treatment Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Atypical Mycobacteriosis Treatment Market, Segmentation By Route Of Admission, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Atypical Mycobacteriosis Treatment Market

• 15.1. Western Europe Atypical Mycobacteriosis Treatment Market Overview
• 15.2. Western Europe Atypical Mycobacteriosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Atypical Mycobacteriosis Treatment Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Atypical Mycobacteriosis Treatment Market, Segmentation By Route Of Admission, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Atypical Mycobacteriosis Treatment Market

• 16.1. UK Atypical Mycobacteriosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Atypical Mycobacteriosis Treatment Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Atypical Mycobacteriosis Treatment Market, Segmentation By Route Of Admission, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Atypical Mycobacteriosis Treatment Market

• 17.1. Germany Atypical Mycobacteriosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Atypical Mycobacteriosis Treatment Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Atypical Mycobacteriosis Treatment Market, Segmentation By Route Of Admission, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Atypical Mycobacteriosis Treatment Market

• 18.1. France Atypical Mycobacteriosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Atypical Mycobacteriosis Treatment Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Atypical Mycobacteriosis Treatment Market, Segmentation By Route Of Admission, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Atypical Mycobacteriosis Treatment Market

• 19.1. Italy Atypical Mycobacteriosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Atypical Mycobacteriosis Treatment Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Atypical Mycobacteriosis Treatment Market, Segmentation By Route Of Admission, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Atypical Mycobacteriosis Treatment Market

• 20.1. Spain Atypical Mycobacteriosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Atypical Mycobacteriosis Treatment Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Atypical Mycobacteriosis Treatment Market, Segmentation By Route Of Admission, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Atypical Mycobacteriosis Treatment Market

• 21.1. Eastern Europe Atypical Mycobacteriosis Treatment Market Overview
• 21.2. Eastern Europe Atypical Mycobacteriosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Atypical Mycobacteriosis Treatment Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Atypical Mycobacteriosis Treatment Market, Segmentation By Route Of Admission, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Atypical Mycobacteriosis Treatment Market

• 22.1. Russia Atypical Mycobacteriosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Atypical Mycobacteriosis Treatment Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Atypical Mycobacteriosis Treatment Market, Segmentation By Route Of Admission, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Atypical Mycobacteriosis Treatment Market

• 23.1. North America Atypical Mycobacteriosis Treatment Market Overview
• 23.2. North America Atypical Mycobacteriosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Atypical Mycobacteriosis Treatment Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Atypical Mycobacteriosis Treatment Market, Segmentation By Route Of Admission, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Atypical Mycobacteriosis Treatment Market

• 24.1. USA Atypical Mycobacteriosis Treatment Market Overview
• 24.2. USA Atypical Mycobacteriosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Atypical Mycobacteriosis Treatment Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Atypical Mycobacteriosis Treatment Market, Segmentation By Route Of Admission, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Atypical Mycobacteriosis Treatment Market

• 25.1. Canada Atypical Mycobacteriosis Treatment Market Overview
• 25.2. Canada Atypical Mycobacteriosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Atypical Mycobacteriosis Treatment Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Atypical Mycobacteriosis Treatment Market, Segmentation By Route Of Admission, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Atypical Mycobacteriosis Treatment Market

• 26.1. South America Atypical Mycobacteriosis Treatment Market Overview
• 26.2. South America Atypical Mycobacteriosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Atypical Mycobacteriosis Treatment Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Atypical Mycobacteriosis Treatment Market, Segmentation By Route Of Admission, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Atypical Mycobacteriosis Treatment Market

• 27.1. Brazil Atypical Mycobacteriosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Atypical Mycobacteriosis Treatment Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Atypical Mycobacteriosis Treatment Market, Segmentation By Route Of Admission, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Atypical Mycobacteriosis Treatment Market

• 28.1. Middle East Atypical Mycobacteriosis Treatment Market Overview
• 28.2. Middle East Atypical Mycobacteriosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Atypical Mycobacteriosis Treatment Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Atypical Mycobacteriosis Treatment Market, Segmentation By Route Of Admission, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Atypical Mycobacteriosis Treatment Market

• 29.1. Africa Atypical Mycobacteriosis Treatment Market Overview
• 29.2. Africa Atypical Mycobacteriosis Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Atypical Mycobacteriosis Treatment Market, Segmentation By Type Of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Atypical Mycobacteriosis Treatment Market, Segmentation By Route Of Admission, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Atypical Mycobacteriosis Treatment Market Competitive Landscape And Company Profiles

• 30.1. Atypical Mycobacteriosis Treatment Market Competitive Landscape
• 30.2. Atypical Mycobacteriosis Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Atypical Mycobacteriosis Treatment Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Sanofi S.A.
• 31.3. Bristol-Myers Squibb
• 31.4. AstraZeneca PLC
• 31.5. Novartis AG
• 31.6. GlaxoSmithKline plc
• 31.7. Eli Lilly and Company
• 31.8. Teva Pharmaceutical Industries Ltd.
• 31.9. Astellas Pharma Inc.
• 31.10. Zydus Pharmaceuticals
• 31.11. Lupin Limited
• 31.12. Gland Pharma Limited
• 31.13. Saphnix Lifesciences Pvt. Ltd.
• 31.14. Gentec Pharmaceutical Group
• 31.15. Octavius Pharma Pvt. Ltd.

32. Global Atypical Mycobacteriosis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Atypical Mycobacteriosis Treatment Market

34. Recent Developments In The Atypical Mycobacteriosis Treatment Market

35. Atypical Mycobacteriosis Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Atypical Mycobacteriosis Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Atypical Mycobacteriosis Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Atypical Mycobacteriosis Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer